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INTRODUCTION 
The most common form of anovulatory infertility is polycystic 
ovary syndrome1. The most typical form, the association of 
hyperandrogenism  and chronic anovulation without specific 
underlying diseases of the adrenal or pituitary glands.  
The principle underlying disorder is insulin resistance resulting 
in hyper insulinemia and hyperandrogenism2,3 in later on life results in 
metabolic Syndrome which predisposes to cardiovascular disease and 
NIDDM in later life4.  
Metabolic syndrome is a combination of several factors which 
may share a common etiology and each of which is a risk factors for 
cardiovascular disease. 
The clustering of Insulin resistance, dysglycemia, dyslipidemia 
and hypertension was originally defined as syndrome X in 19885 
Metabolic syndrome includes general obesity (as reflected by 
BMI defined as wt in kg/ht in m2 central obesity as reflected by waist 
circumference or waist hip ratio) dyslipidemia (as reflected by Low 
HDL and High TGL levels) hyperglycemia, high blood pressure and 
resistance to action of insulin. 
The risk of diabetes and cardiovascular disease with polycystic 
ovarian syndrome necessitates the awareness to detect it at an earlier 
stage. The identification of these insults in the preclinical state will 
lead on to delay in clinical manifestation and the postponement of 
metabolic morbidity. 
The current study focuses this problem to identify early markers 
and to set guidelines for defining the metabolic syndrome among 
PCOS patients. 
 
 
 
 
AIM OF THE STUDY 
To study the significance of: 
1. Anthropometric Measurements 
2. Insulin Resistance (Fasting Glucose) 
3. Lipid Profile (TGL/HDL Ratio) 
4. Hypertension (Blood Pressure) in Polycystic ovarian disease. 
MATERIALS AND METHODS 
Patients who attended the Endocrinology OPD, Institute of Obstetric 
and Gynecology with history and clinical examination suggestive of 
polycystic ovaries were analyzed and those who fit in inclusion criteria were 
taken for study numbering one hundred and  nine.  
A control group consisting of hundred women were also studied. The 
group had spontaneous, regular cylical menstrual flow and with out 
hyperandrogenic features. All were euthyroid and euprolactinemic.  
Study and Control group were in the age group 16-35. 
Period of study was between Oct 2005 to Sep 2006. 
Inclusion Criteria: 
1. Less than 40 years 
2. USG findings of Polycystic ovaries 
3. Hyperandrogenic features 
4. Menstrual disorders. 
Exclusion Criteria: 
1. Prior known endocrine or medial disorder 
2. Patients with chronic infection 
3. Patients on hormone therapy.   
A detailed menstrual history was taken. History regarding obesity, 
acne, hirsutism and infertility was taken.  
Family History of Diabetes Mellitus / Hypertension / Polycystic 
ovarian disease, history suggestive of obesity, irregular cycles, infertility was 
enquired. History of PIH / GDM/Recurrent pregnancy loss) secondary 
infertility enquired. 
Physical Examination:  
A thorough clinical examination including cardiovascular, Respiratory 
and Central nervous system were done.  
Measurement of height was done with barefoot and medial malleoli 
touching. 
Weight was measured by a standard weighing scale. 
Body mass index was calculated 
 Weight in kg 
Body mass index:    
 Height in M2 
Waist and hip measurements in cms were taken. Waist is measured at 
the narrowest point between highest point between iliac crest. Hips are 
measured at the maximal points of buttocks in cms. Waist / Hip ratio of 0.85 
and above were taken as clinically significant. 
Waist circumference is taken and more of 88cms is predictive of 
abnormality. 
Blood pressure was recorded using standard sphygmomanometer in 
right upper limb in sitting posture. 
Detailed physical examination for evidence of hyperandrogenism was 
done. 
 
Features of hyperandrogenism included: 
1. Hirsutism 
2. Acne 
3. Temporal Recession 
4. Clitoromegaly 
5.  Masculinization 
Hirsutism was assessed by Ferriman-Gallway Scoring F and G score 
of 9 and above were diagnostic. 
Breasts were examined for evidence of galactorrhoea. 
Ultra sound evidence of pelvic visera was done for diagnosis of 
polycystic ovarian disease using L and T ultrasound scanner. 
Tran abdominal scanning with full bladder using linear transducer was 
done. 
Uterine measurements was taken and endometrial thickness was 
accurately measured. 
All regularly menstruating women were scanned during the follicular 
phase and those with irregular menstruation and secondary amenorrhea were 
scanned at random. 
Criteria used for diagnosing polycystic ovaries are . 
ADAMS CRITERIA : More than eight peripherally oriented cysts or 
less than 10mm surrounded by increased stromal mass and ovarian volume 
of more than nine cc. 
Ovaries were scanned in transverse as well as linear phase  to as to 
obtain length width and thickness of each ovary. Ovarian volume was 
calculated using the formula 0.523 x Length x Width x Thickness. 
Biochemical and Hormonal Profile:  
Blood for lipid profile, fasting glucose, hormonal status were taken in 
the morning with subjects in about 12 hrs fasting state. Venous blood was 
obtained and sent for biochemical and hormonal studies. 
Lipid profile and blood glucose measurement: 
Fasting blood glucose and lipid profile were done in Department of 
Biochemistry MMC using commercially available kits. 
Total Cholestrol, HDL, and triglycerids were estimated by enzymatic 
methods. 
Hormonal Assay: TSH, Prolactin were done in the department of 
endocrinology using radioimmuno assay technique. Of the 109 study group 
eight patients had elevated TSH level (more than 5 IU/l) and 1 had elevated 
prolactin (more than 30 mg/ml) and hence 9 were excluded from further 
study and analysis. 
THE ROTTER-DAM REVISED DIAGNOSTIC CRITERIA OF POLYCYSTIC 
OVARY SYNDROME: 
1990 Criteria (both 1 and 2) 
1. Chronic anovulation and 
2. Clinical and/or biochemical signs of hyperandrogenism and 
exclusion of other etiologies  
 
Revised 2003 criteria (2 out of 3) 
1. Oligo – or anovulation 
2. Clinical and / or biochemical signs of hyperandrogenism 
3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal 
hyperplasia, androgen-secreting tumors, Cushing’s syndrome). 
The revised criteria having sufficient sensitivity and specificity to define 
PCO are “presence of 12 or more follicles in each ovary measuring 2-9 
mm in diameter and increased ovarian volume >10 ml 
REVIEW OF LITERATURE 
In 1935, Irving F.Stein and Michael L. Leventhal first described a 
symptom complex associated with anovulation6. It was later called as 
STEIN-LEVENTHAL SYNDROME.  
The PCOS is the commonest endocrine disturbance affecting women. 
The Syndrome is denoted by combination of hyperandrogenism and 
ovulatory dysfunction, with enlarged polycystic ovaries by ultrasound, in the 
absence of non-classical adrenal hyperplasia, Cushing’s syndrome and 
androgen producing tumors. 
The Characteristic polycystic ovary emerges when a state of 
anovulation persists for any length of time.. The polycystic ovary is the 
result of a functional derangement, not a specific central or local defect 
(Leon Speroff, 1999.7 
HORMONAL MILIEU IN PCO IS AS FOLLOWS: 
In patients with persistent anovulation, the average daily production of 
estrogen and androgen is both increasesd and dependent upon LH 
stimulation. This is reflected in higher circulating levels of Testosterone, 
Androstenedione, Dehydroepiandrosterone, DHEAS, 17 (OH) Progesterone 
and Estrone (De Van GW, 1975). The Testosterone, Androstenedione and 
DHEA are secreted directly by the ovary while DHEAS is almost 
exclusively an adrenal contribution 8. 
In PCOS, the ovaries donot secrete enough Estradiol, the level of 
which is equivalent to early follicular phase concentrations. The increased 
Estrogen is due to peripheral conversion of increased amounts of 
Androstenedione to Estrone. The consequence of raised Estrogen levels 
results in alteration in H-P-O axis. 
Clinical Consequences of Persistent anovulation9 
1. Reproductive Morbidities associated with PCOS are 
• Infertility 
• Oligoamenorrhoea 
• Increased Pregnancy loss 
• Increased PIH, Diabetes mellitus during pregnancy 
• Endometrial carcinoma 
 
2. Hyperandrogenic features 
• Acne 
• Oily skin 
• Hirsutism 
3. Other metabolic morbidity in later life 
• Diabetes mellitus 
• Hypertension 
• Dyslipidemia 
• Coronary artery disease, 7 fold increased risk for infarction. 
Insulin resistance is defined as decreased glucose response to a given 
amount of insulin. Resistance to insulin stimulated glucose uptake is a 
relatively common phenomenon but is only one component of a condition 
called metabolic syndrome10 
CRITERIA FOR METABOLIC SYNDROME WITH POLYCYSTIC OVARIAN 
DISEASE 
(Three out of Five qualify for the syndrome (NCEP)11 
1. Hypertension: B.P. more than  130/85 mm/Hg or higher 
2. Abdominal obesity (waist hip circumference more than 88cm / waist 
hip ratio morethan 0.85) 
3. Serum TG morethan 150mg/dl 
4. Serum HDL lessthan 50mg/dl 
5. Serum fasting glucose – 110 mg/dl or more. 
Summary of 2003 polycystic ovary syndrome (PCOS) consensus 
regarding screening for metabolic disorders12. (Rotterdam) 
Summary of Consensus: 
1. No test of insulin resistance are necessary to make the diagnosis of 
PCOS, nor are they needed to select treatments. 
2. Obese women with PCOS should be screened for the metabolic tests. 
3. Further studies are necessary in nonobese women with PCOS to 
determine the utility of these tests, although they may be considered if 
additional risk factors of insulin resistance such as a family history of 
diabetes, are present.  
A large number of epidemiological studies have shown there is a 
relationship between low birth weight and subsequent risk of 
development of type 2 diabetes mellitus13 . insulin resistance14 and 
other features of metabolic syndrome such as hypertension15. 
Fetal and Neonatal life are critical periods for development and 
growth of systems involved in the pathology of metabolic syndrome.  
Striking evidence show there is as much as 18 fold increase in the risk 
of developing the metabolic syndrome on comparing the lowest birth 
weight individuals with the highest birth weight individuals16. 
DEVELOPMENTAL ORIGINS 
THRIFTY PHENOTYPE HYPOTHESIS: 
This hypothesis status that in response to poor fetal nutrition the 
compromised fetus will adopt a number of strategies to maximize its channel 
of survival postnatally.  
Firstly growth of brain is spared at the expense of other tissue such as 
muscle, kidneys and endocrine pancreas (Rudolph 1984) in addition 
metabolic programming is proposed to occur in the manner  beneficial to 
survival under the conditions of poor postnatal nutrition. Foetus is 
programmed to store nutritions such as fat. Problems are proposed to occur if 
malnourished Foetus is born in conditions of adequate or over nutritions. 
This conflicts the earlier programming and obesity, type 2 diabetes and other 
features of metabolic syndrome. 
Foetal Insulin Hypothesis: 
An alternative hypothesis to explain the link between low birthweight 
and type 2diabetes was suggested by Hattersley and Tooke in 199917. In this 
hypothesis, a genetic susceptibility to insulin resistance or beta cell 
dysfunction leads to retard growth in utero due to impaired insulin-mediated 
foetal growth and thus to reduced birthweight. This insulin-resistant or 
deficient phenotype would then show metabolic impairments in adulthood.  
Rare mutations have been identified in the glucokinase gene that are 
associated with a low birthweight and the development of a rare monogenic 
form of diabetes; maturity onset diabetes of the young18. 
Recent studies have identified interesting gene-birth size interaction in 
the case of peroxisome proliferators-activated receptor gamma 
2(PPARgama2) and polymorphisms19. 
 
 
 
  
 
 
Genes known to alter the risks of metabolic syndrome diseases are: 
1. CALPAIN-10 calpain-10 is a ubiquitously expressed cysteine 
protease important in the modifications of processing of proteins in the 
cell .calpan 10 is likely to be important in Beta cell apoptosis. 
Bairer20 have show that calpain 10 polymorphisms are associated with 
insulin resistance. Lynn21 have shown a correlation between Calpain 
10 genotype and response to an oral glucose load. 
 
THE PPAR GAMA GENE 
2. PPAR gama gene lodes for a protein that is a key controller of gene 
transcription in adipocytes. Severe mutations of the PPAR gama gene 
cause a disorder with many features of the metabolic syndrome22. 
3. The Kir 6.2 and SUR genes  
In pancreatic beta cells, ATP Sensitive Potassium channels (KATP) are 
critical components for the control of appropriate insulin secretion 
4. The Hepatocyte Nuclear Facator 1 Alpha 
HNF 1 Alpha is a transcription factor primarily expressed in liver but also 
in beta cell. Rare, severe mutations cause MODY. A common variant of 
the HNF 1Alpha gene predisposes to type 2 diabetes in the  
Oji-Cree population of Canada. This isolated native Indian population 
had highest prevalence of type 2 diabetes in the world (Hegele)23.  
 
 
5. The Hepatocyte Nuclear Factor 4 Gene 
The chromosome (20q12-13.1) contains the HNF 4alpha gene (McCarthy 
and Gloyn et al 2003). P2 promoter controls the activation version of 
HNF 4 Alpha gene that it is a critical point of transcription factor that 
controls the differentiation and maintenance of beta cell phenotype24 (Boj 
and Thomas). 
6. The GCK GENE 
A common variant in the promoter of the glucokinase (GCK) gene alters 
fasting glucose. Glucokinase is the glucose sensing enzyme of the beta 
cell (Matschinsky  1990). GCK mutation cause a relatively mild and 
stable increase fasting glucose concentration. (Stride and Hattersley 
2002)25. 
OBESITY 
Obesity can be classified as 
• Gynoid type & 
• Android type 
Gynoid obesity refers to distribution in lower body – (Femoral and 
gluteal region) 
Android obesity refers to central body distribution. 
Whereas Gynoid fat is more resistant to catecholamines and sensitive 
to insulin. 
Android fat is more sensitive to catecholamines and less sensitive to 
insulin and more active metabolically. 
Android distribution is associated with, 
• Hyperinsulinemia 
• Impaired Glucose tolerance 
• Diabetes mellitus 
• Increase in androgen production rates 
• Decrease in SHBG and 
• Increase in free Testosterone and Estrogen 
Android – Central body-obesity is associated with cardiovascular risk 
factors, including Hypertension and adverse cholesterol lipoprotein profiles 
(26). 
Waist: Hip ratio had been used as a measure of estimating the degree 
of upper to lower body obesity, as the ratio accurately predicts the 
intraabdominal fat which is greater in android obesity 27. 
However, studies have demonstrated that the more easily determined 
circumference of the waist is better predictor of android abdominal fat28 
At any given level of BMI, an increase in android fat increases the 
cardio vascular risk. 
A waist circumference greater than 90cm (35”) now 88cm in women 
in predictive of abnormal endocrinologic and metabolic function 
circumference>88 cm is most and is associated with an increased risk of 
cardiovascular morbidity as mentioned29 .Waist hip ratio is strongly 
associated with metabolic syndrome. The WORLD HEALTH 
ORGANISATION clinical criteria for metabolic syndrome used BMI >30  
or WHR interchangeably (WHO-1999) 
    Wt in kg 
BMI is calculated by  
    Ht in M2 
BMI > 27 warrants treatment 30. 

OLIGOMENORRHOEA: 
Oligomenorrhoea is defined as infrequent and irregularly timed 
episodes of bleeding usually occurring at intervals of more than 35 days and 
upto 6 months. 
HIRSUTISM: 
The increased androgen leads on to Hirsutism and Acne. Hirsutism 
should be regarded as an increase in sexually stimulated terminal hair. 
Among the ovarian causes, PCOS, is the most common cause of androgen 
excess seconded by ovarian neoplasms. 
Several scoring system are available to assess Hirsutism, the most 
clinically useful being that of Ferriman and Gallway (1961) was uses a score 
of 0-4 for each area of the body.31 Score of >9 taken as significant. 
HIRSUTISM – FERRIMAN GALLWAY SCORING SYSTEM 
1. Upper lip 
1 – A few hairs at anterior margin 
2 – small moustache at anterior margin 
3 – Moustache extending halfway from outer margin 
4 – Moustache extending to midline 
2. Chin 
1 – A few scattered hair 
2 – Small concentration of scattered hairs 
3 – Light complete cover 
4 – Heavy complete cover 
3. Chest 
1 – Circum areolar hairs 
2 – Additional midline hairs 
3 – Fusion of these areas with three quarter cover 
4 – Complete cover 
4. Upper Back 
1 – Few scattered hairs 
2 – Rather more, still scattered 
3 – Light complete cover 
4 – Heavy complete cover 
5. Lower Back 
1 – A Sacral tuft of hair 
2 – With some lateral extension 
3 – Three Quarter cover 
4 – Complete cover 
6. Upper Abdomen 
1 – A few midline hairs 
2 – Rather more still midline 
3 – Half cover 
4 – Full cover 
7. Lower Abdomen 
1 – A few midline hairs 
2 – Midline steak of hair 
3 – Midline band of hair 
4 – Inverted ‘V’ shaped growth 
8. Upper arm 
1 – Sparse growth affecting not more that a quarter of limb surfaces 
2 – More cover still incomplete 
3 – Light complete cover 
4 – Heavy complete cover 
9. Thigh 
1 – Sparse growth affecting not more than a quarter of limb surfaces 
2 – More cover still incomplete 
3 – Light complete cover 
4 – Heavy complete cover 
 INSULIN RESISTANCE: 
Insulin Resistance is defined as a reduced glucose response to a given 
amount of insulin.  
A part from the association of insulin resistance with PCOS, Where 
defect is in post binding signaling pathways, rare clinical models with insulin 
resistance has been described. In those rare clinical models defects is in 
insulin receptor either due to point mutation (Type A syndrome) or due to 
autoantibodies against insulin receptor associated with autoimmune disease.  
PCOS is associated with peripheral insulin resistance and 
hyperinsulinemia and the degree of both abnormalities is amplified by the 
presence of obesity. Studies had showed that women with PCOS have 
peripheral insulin resistance similar in magnitude to that seen in patients 
with non-insulin dependent, diabetes mellitus (NIDDM)32. 
Hyperinsulinemia consequent to peripheral insulin resistance 
represents a mechanism to overcome the impaired insulin-mediated glucose 
use in women with PCOS. Obesity, commonly associated with PCOS (50% 
cases) has an additive negative effect on insulin resistance as indicated by 
the reduced hepatic insulin sensitivity in obese PCOS women beyond that 
associated with obesity alone 33. 
Serine instead of Tyrosine phosphorylation is an “off” mechanism for 
glucose transport, but an ‘on” mechanism for P450 C17 enzyme activity 34 
 
 
 
 
 
 
 
 Combination of increased androgen secretion and insulin resistance 
has been reported in both obese and non obese anovultory women35  
Hyperandrogenism and hyperinsulinemia are not explained solely by 
obesity; However the presence of obesity adds the insulin resistance and 
hyperinsulinemia associated with obesity to that which is specifically unique 
to the anovulatory polycystic ovary state36. 
Fasting plasma glucose concentration depends primarily on the rate of 
hepatic glucose release which in turn is regulated by insulin concentration. 
In addition, hyperandrogenism and insulin resistance are often 
associated with Acanthosis nigricans37. 
Acanthosis nigricans is a grey-brown velvety sometimes verrucous, 
discoloration of the skin usually at the neck, groin, axillae and under the 
breast which is a marker for insulin resistance. It is most highly correlated 
with the magnitude of peripheral insulin resistance. 
The state of chronic hyperinsulinemia represents a compensatory 
response to the target tissue problem. If the insulin levels necessary to 
suppress free fatty acid levels cannot be achieved, then the increase in free 
fatty acid leads to increased in hepatic glucose production and 
hyperglycemia. 
Hyperinsulinemia leads to hypertension and an increased risk of 
Coronary heart disease38. Resistance to insulin is further associated with 
increased triglycerides, small dense lipoproteins and decreased HDL-
Cholesterol levels, a potent bad combination that promote coronary artery 
disease39. 
Hyperinsulinemia act in genetically predisposed women as a “Second 
Hit" to unmask latent abnormalities in steroidogenesis 1997. 
a). Ovary 
b). Adrenal cortex and  
c). Other organs 
 Paradoxically function as if responding to hyperinsulinemic 
state inspite of resistance to effects of insulin on glucose metabolism. 
INSULIN RESISTANCE AT PUBERTY 
Insulin resistance normally develops during the process of puberty in 
association with the rise in secretion of insulin, IGF-1, GH and 
gonadotropin. 
PUBERTY 
PHYSIOLOGICAL EVENTS 
Growth Hormone 
Insulin Resistance 
Insulin Secretion 
                                                      IGF -1 
   IGFBP -1 
            SHBG 
 
Hyperinsulinemia 
 
Bioavailability 
IGFS & Steroids 
 These changes may synergistically enhance gonadotropin action on 
the ovary. It contributes to the transition of hyperandrogenism from the 
adrenal to the ovary. 
Insulin resistance and hyperinsulinemia appear to extend beyond 
puberty in women who have inherent cellular defects of insulin resistance 
and are thus destined to develop PCOS. 
Although the adverse effect is present in anovulatory women with 
polycystic ovaries, hypertension is not encountered in these women until 
later in life, not in their reproductive years40. 
Hyperinsulinemia and polycystic ovaries are also associated with an 
increased production of Plasminogen Activator Inhibitory type (PAI – 1). 
Increased PAI – 1 levels are correlated with an increased risk of coronary 
heart disease, impaired fibrinolysis may effect vascular tissue changes 
associated with vascular disease. 
 
 
LIPID PROFILE IN PCOS 
Lipid profile in androgenized women with polycystic ovaries (who are 
also exposed to reltively low estrogen levels over time) in similar to the male 
pattern with higher levels of cholesterol, triglycerides and LDL Cholesterol 
and lower levels of HDL – Cholesterol, and this abnormal pattern is 
independent of body weight41 
An adverse lipid profile is a distinguishing feature of these patients 
even when body mass index, insulin and age are controlled in case control 
studies42. 
Lipids and Lipoproteins: 
The lipoprotein profile in obese women with PCOS is generally 
characterized by elevated plasma triglyceride and reduced high density 
lipoprotein (HDL) Cholesterol concentrations, wild 2002.43 
A contributing factor to the abnormal lipid pattern in many of these 
patients is hyperinsulinemia. 
Insulin resistance may be a more significant factor than androgens in 
determining the abnormal lipoprotein profile in overweight, anovulatory 
women. 
The metabolic syndrome is accompanied by a 2 fold increase in risk of 
CVD and as fold increase in the risk of type 2 DM44. 
The aetiological mechanisms underspinning insulin resistance and 
reproductive abnormalities in women with PCOs are : 
• Genetic Contributions to both reproductive and metabolic features45  
• Defects in adipose tissue Lipolytic cascades 46 
• Inflammation Mediators leading to insulin resistance47 
• Fetal programming effect48 
• Primary ovarian hypersensitivity to insulin, leading firsty to altered 
hormonal milieu and then to alterations in body fat distribution 
(central > peripheral) with possible feedback towards greater insulin 
resistance. 
Insulin resistance was seen at higher BMI level and was largely 
determined by increased Truncal-abdominal fat mass in PCOs 49 women 
with PCOs with 42 BMI matched control study of HOLTE (1994) 49 
In a study by Escobar- Morreale50 2004, has shown greater waist 
circumference or waist hip ratio in women with PCOs independent of 
BMI. 
Recent study by Yildrim, Sabir and Kaleli51 2003 intraabdominal fat 
preperitoneal fat and subcutaneous fat thickness by USG found 2-fold higher 
visceral and preperitoneal fat thickness in women with PCOS despite  near 
identical BMI and clinical subcutaneous fat content. 
Women with PCOs accure more metabolic abnormalities with 
increasing BMI compared with women without PCOs which is generally in 
keeping with greater increments in insulin resistance with increasing BMI 
(Talbott52 2004. Aprindonindze)53 2004. 
In a study by Dokras54  2005 found serum triglycerides / high density 
lipoprotein cholesterol (TG / HDL-C) ratio correlated with insulin resistance. 
Serum TG /HDL-C > 3.2 had a high sensitivity and specificity for detection 
of metabolic syndrome in women with PCOS. The TG/HDL-C ratio may 
serve as a screening tool and needs to be prospectively validated. 
DISCUSSION 
Insulin resistance is linked to a Spectrum of metabolic abnormalities 
that can predate the onset of diabetes and cardiovascular disease by many 
years. Such abnormalities include lipid perturbance, hemostatic alteration, 
lowgrade chronic inflammation, high blood pressure endothelial dysfunction, 
body fat redistribution and glucose intolerance. 
The Lipoprotein profile in PCOS women may result in Lipid alteration 
leading to metabolic disturbances, cardiovascular disease, endothelial 
dysfunction and hyperinsulinemia. In contrast to the caucasion population, 
Asian women have increased body fat content in spite of Low BMI. visceral 
adiposity serves as an important marker for future misery relating it to 
PCOS.  
Our study highlights the importance of evaluating the markers of 
metabolic syndrome in PCOD women. BMI and visceral adiposity directly 
correlate with lipoprotein abnormalities. Insulin resistance, a close associate 
of metabolic syndrome is present in significant population amongst the study 
group. Hypertension has  significant correlation. 
In my study, prevalence  of metabolic syndrome was higher in women 
with PCOS (66%) C.I 1.98,9.02   is comparable to the study done by 
ANUJA DOKRAS AND MELINDA(ACOG JULY/2005)  where age 
adjusted prevalence of metabolic syndrome was  47.3%. 
Elevated fasting glucose was detected least frequently among patients 
with PCOS in the study by Dokras and Bradley was 12.6 ± 4.0% and these 
were not significantly different compared with their control group. 
In my study, Fasting blood sugar was found to be elevated in 6% of 
PCOD compared to control group (2%) 
• In most common abnormality in PCOS group in my study was increased 
BMI and WHR> .85 was 74%, Low HDL 39% and high triglycerides 
63% which is quite comparable to similar study done by Dokras & 
Melinda. BMI –(72.3%) Low HDL-C (63.7%) and high Triglycerides 
46.8%. 
• The high incidene of metabolic syndome could be explained to be due to 
variation in the ethnicity, Racial, genetic and environmental factors which 
is found to be more in South Asian when compared to Europeans. 
 
CONCLUSION 
PCOS, a clinical entity is a complex association of metabolic 
disturbances expressing in different ways both clinically and chemically. The 
focus of our study is to unreveil its association. Compared to the western 
literature, PCOS, has profoundly present in our Asian population. 
Body weight has direct correlation with the presence of PCOS as 
weight, BMI, waist hip ratio increasing which tells us the importance of 
documenting anthropometic measurements. Clinical scenerio inclusive of 
Hypertention, fasting lipid abnormality goes hand in hand amongst PCOS 
Patients. 
The Significane of elevated fasting glycemic status was not 
appreciably present which precludes the importance of documenting post 
glucose challenge which will unmask the impairment of glucose tolerance. 
The role of treating physician is expanded in cases of polycystic 
orarian syndrome after realising its close association whith chemical 
abberations resulting in the Misery of Systemic abnormalities. Till we 
understand the real etiological factor which result in PCOS, the 
responsibility to detect and treat the tentacles of morbid associations as 
highlighted in our study.  
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1 Santha 26 23.5 84 0.82 120 80 0 1.67 4.07 75 104 119 39.6 2.9 104 2 0 3 2 0 2 0 1 0 2 0 1 2
2 Revathy 26 24 73 0.79 110 70 0 2.32 7.5 82 161 169 32.5 3.3 161 2 0 3 2 0 2 0 1 1 1 0 2 2
3 Asha 25 23 94 0.89 130 86 0 1.002 13.4 83 162 138 31.7 4.2 162 2 1 2 2 1 1 1 1 0 1 0 4 1
4 Devaki 25 24 77 0.84 110 70 0 2.119 19.26 102 117 158 52.8 3.03 117 2 0 2 2 0 2 0 0 1 2 0 1 2
5 Ambika 25 31 90 0.9 116 70 0 1.06 7.8 70 191 147 48.2 3.06 191 2 1 2 4 1 2 0 1 0 2 0 3 1
6 Indu 32 29 87 0.85 100 60 0 3.21 12.2 74 172 91 43 2.11 173 2 0 4 3 0 2 0 1 0 2 0 1 2
7 Radha 26 35 101 1.2 130 90 0 2.78 14.9 93 194 70 58.6 1.2 194 2 1 3 4 1 1 1 0 0 2 0 3 1
8 Vijayalakshmi 27 29 74 0.81 140 80 0 2.41 8.74 81 200 76 45.2 1.68 200 2 0 3 3 0 2 1 1 0 2 0 2 2
9 Aarthy 23 24 70 0.76 130 70 0 4.01 1.62 75 140 78 43 1.81 140 2 0 2 2 0 2 1 1 0 2 0 2 2
10 Shoba 21 31 89 0.82 120 80 0 3.167 10.4 92 159 138 40.7 3.45 159 2 1 2 4 0 2 0 1 0 1 0 2 2
11 Radhika 22 34 74 0.76 130 80 0 2.21 8.72 80 180 132 65 2.03 180 2 0 2 4 0 2 1 0 0 2 0 1 2
12 Shenbagum 23 24.2 89 0.9 110 80 0 3.34 12.6 82 140 72 43 1.67 140 2 1 2 3 1 2 0 1 0 2 0 3 1
13 Roshani 20 23.9 87 0.88 110 70 0 2.101 7 75 157 118 57.6 2.07 157 2 0 1 2 1 2 0 0 0 2 0 1 2
14 Devi 23 29 84 0.8 130 80 0 2.041 9.4 92 160 109 32.5 3.3 160 2 0 2 3 0 2 1 1 0 1 0 2 2
15 Vasundara 22 22.6 73 0.85 110 80 0 1.76 2.36 80 190 135 54.3 2.5 190 2 0 2 2 0 2 0 0 0 2 0 0 2
16 Muniammal 24 30 85 0.9 110 60 0 2.34 5.71 75 149 167 43.7 2.5 149 2 0 2 3 1 2 0 1 1 2 0 3 1
17 Sudha 26 34 84 0.92 100 70 0 1.07 4.02 76 159 90 36.4 2.6 159 2 0 3 4 1 2 0 1 0 2 0 2 2
18 Seetha 28 24.7 80 0.81 120 80 0 3.01 1.01 80 223 70 58.1 1.2 223 2 0 3 3 0 2 0 0 0 2 0 0 2
19 Manju 25 23 73 0.8 130 70 0 1.12 6.2 91 194 61 38.6 1.605 194 2 0 2 2 0 2 1 1 0 2 0 2 2
20 alamelu 27 23 76 0.9 110 74 0 1.002 4.07 80 156 92 62.6 1.48 156 2 0 3 2 1 2 0 0 0 2 0 1 2
21 Hema 28 22 90 0.91 130 86 0 5.11 7.826 81 162 66 43.3 1.53 162 2 1 3 2 1 1 1 1 0 2 0 4 1
22 Sunitha 24 24 94 0.9 130 70 0 1.69 5.314 85 168 135 51.5 2.64 168 2 1 2 2 1 2 1 0 0 2 0 3 1
23 Sumathi 26 30 81 0.8 110 60 0 2.804 8.72 80 121 70 54.3 1.29 121 2 0 3 3 0 2 0 0 0 2 0 0 2
24 Aruna 23 30.6 75 0.75 130 80 0 4.11 6.101 79 190 90 43.7 2.09 190 2 0 2 4 0 2 1 1 0 2 0 2 2
25 Rekha 22 23.2 86 0.84 140 90 0 2.04 8.443 75 159 132 38.1 3.42 159 2 0 2 2 0 1 1 1 0 1 0 2 2
26 Selvi 21 24 75 0.88 116 80 0 4.169 7 83 180 72 65 1.107 180 2 0 2 2 1 2 0 0 0 2 0 1 2
27 Saradha 25 24 74 0.81 116 76 0 2.54 5.601 85 168 107 43 7 168 2 0 2 2 0 2 0 1 0 1 0 1 2
28 Sublakshmi 27 30 88 0.86 130 70 0 1.76 16.26 90 154 86 46.4 1.91 184 2 1 3 3 1 2 1 1 0 2 0 4 1
29 Anajli 25 30.6 90 0.91 120 80 0 3.32 4.8 89 161 135 47 2.87 161 2 1 2 4 1 2 0 1 0 2 0 3 1
30 Swarana 24 30.3 81 0.83 140 80 0 2.41 7.5 87 143 115 35.2 3.28 143 2 0 2 4 0 2 1 1 0 1 0 2 2
31 Janaki 26 33 112 1.2 140 90 0 1.12 6.29 87 143 115 35.2 3.28 143 2 1 3 4 1 1 1 1 0 1 0 4 1
32 Jothi 31 30 88 0.8 110 70 0 1 6.79 70 194 61 38 1.6 194 2 1 4 3 0 2 0 1 0 2 0 2 2
33 Yeshoda 21 22 96 0.9 100 70 0 2.1 7 75 168 66 48.3 1.53 168 2 1 2 2 1 2 0 1 0 2 0 3 1
34 Radha 22 29 73 0.74 130 80 0 2.78 11.2 85 121 70 50 1.2 121 2 0 2 3 0 2 1 1 0 2 0 2 2
35 Vasanthi 26 23 81 0.8 110 70 0 3.2 11.4 92 110 72 65 1.107 110 2 0 3 2 0 2 0 0 0 2 0 0 2
36 Sujatha 30 22 85 0.86 120 80 0 3.17 11.6 80 180 135 51.6 2.64 180 2 0 3 2 1 2 0 0 0 2 0 1 2
37 Rajeswari 26 33.1 64 0.72 130 80 0 2.117 8.06 73 223 107 44 2.4 223 2 0 3 4 0 2 1 1 0 2 0 2 2
38 Sumathi 20 31 90 0.91 130 70 0 3.21 7.03 74 170 66 43.3 1.5 170 2 1 1 4 1 2 1 1 0 2 0 4 1
39 Surya 28 29 94 0.9 150 90 0 4.07 5.06 86 159 90 36.4 2.6 159 2 1 3 3 1 1 1 1 0 2 0 4 1
40 Reshma 20 24.2 80 0.8 140 80 0 0.06 6.71 88 194 61 38 1.605 194 2 0 1 3 0 2 1 1 0 2 0 2 2
41 Kamali 21 26 82 0.82 110 70 0 1.002 4.02 78 103 90 36.4 2.6 103 2 0 2 3 0 2 0 1 0 2 0 1 2
42 Karthika 25 30 79 0.75 120 80 0 2.016 4.06 74 172 61 38 1.6 172 2 0 2 3 0 2 0 1 0 2 0 1 2
43 Renuka 28 22 79 0.78 110 70 0 2.74 7.73 92 186 136 51 1.31 186 2 0 3 2 0 2 0 0 0 2 0 0 2
44 Chitra 20 23 79 0.77 120 70 0 2.61 9.06 89 164 107 43 2.42 164 2 0 1 2 0 2 0 1 0 2 0 1 2
45 Kalpana 19 26 92 0.9 118 74 0 1.84 5.74 90 144 61 38 1.607 144 2 1 1 3 1 2 0 1 0 2 0 3 1
46 Vasundara 22 22.6 73 0.85 110 80 0 1.76 2.36 80 190 135 54.3 2.5 190 2 0 2 2 0 2 0 0 0 2 0 0 2
47 Muniammal 24 30 85 0.9 110 60 0 2.34 5.71 75 149 167 43.7 2.5 149 2 0 2 3 1 2 0 1 1 2 0 3 1
48 Sudha 26 34 84 0.92 100 70 0 1.07 4.02 76 159 90 36.4 2.6 159 2 0 3 4 1 2 0 1 0 2 0 2 2
49 Seetha 28 24.7 80 0.81 120 80 0 3.01 1.01 80 223 70 58.1 1.2 223 2 0 3 3 0 2 0 0 0 2 0 0 2
50 Latha 25 23 73 0.8 130 70 0 1.12 6.2 91 194 61 38.6 1.605 194 2 0 2 2 0 2 1 1 0 2 0 2 2
51 Janaki 27 23 76 0.9 110 74 0 1.002 4.07 80 156 92 62.6 1.48 156 2 0 3 2 1 2 0 0 0 2 0 1 2
52 Hemalatha 28 22 90 0.91 130 86 0 5.11 7.826 81 162 66 43.3 1.53 162 2 1 3 2 1 1 1 1 0 2 0 4 1
53 Kumari 24 24 94 0.9 130 70 0 1.69 5.314 85 168 135 51.5 2.64 168 2 1 2 2 1 2 1 0 0 2 0 3 1
54 Prema 26 33 112 1.2 140 90 0 1.12 6.29 87 143 115 35.2 3.28 143 2 1 3 4 1 1 1 1 0 1 0 4 1
55 Meena 31 30 88 0.8 110 70 0 1 6.79 70 194 61 38 1.6 194 2 1 4 3 0 2 0 1 0 2 0 2 2
56 Jayalakshmi 21 22 96 0.9 100 70 0 2.1 7 75 168 66 48.3 1.53 168 2 1 2 2 1 2 0 1 0 2 0 3 1
57 Jeeva 22 29 73 0.74 130 80 0 2.78 11.2 85 121 70 50 1.2 121 2 0 2 3 0 2 1 1 0 2 0 2 2
58 Rekha 26 23 81 0.8 110 70 0 3.2 11.4 92 110 72 65 1.107 110 2 0 3 2 0 2 0 0 0 2 0 0 2
59 Indra 30 22 85 0.86 120 80 0 3.17 11.6 80 180 135 51.6 2.64 180 2 0 3 2 1 2 0 0 0 2 0 1 2
60 Rajathi 26 33.1 64 0.72 130 80 0 2.117 8.06 73 223 107 44 2.4 223 2 0 3 4 0 2 1 1 0 2 0 2 2
61 Komala 20 31 90 0.91 130 70 0 3.21 7.03 74 170 66 43.3 1.5 170 2 1 1 4 1 2 1 1 0 2 0 4 1
62 Kavitha 28 29 94 0.9 150 90 0 4.07 5.06 86 159 90 36.4 2.6 159 2 1 3 3 1 1 1 1 0 2 0 4 1
63 Jenny 20 24.2 80 0.8 140 80 0 0.06 6.71 88 194 61 38 1.605 194 2 0 1 3 0 2 1 1 0 2 0 2 2
64 Ushanandhini 21 26 82 0.82 110 70 0 1.002 4.02 78 103 90 36.4 2.6 103 2 0 2 3 0 2 0 1 0 2 0 1 2
65 leela 26 23.5 84 0.82 120 80 0 1.67 4.07 75 104 119 39.6 2.9 104 2 0 3 2 0 2 0 1 0 2 0 1 2
66 sumathi 26 24 73 0.79 110 70 0 2.32 7.5 82 161 169 32.5 3.3 161 2 0 3 2 0 2 0 1 1 1 0 2 2
67 Sujatha 25 23 94 0.89 130 86 0 1.002 13.4 83 162 138 31.7 4.2 162 2 1 2 2 1 1 1 1 0 1 0 4 1
68 Sreedevi 25 24 77 0.84 110 70 0 2.119 19.26 102 117 158 52.8 3.03 117 2 0 2 2 0 2 0 0 1 2 0 1 2
69 yamuna 25 31 90 0.9 116 70 0 1.06 7.8 70 191 147 48.2 3.06 191 2 1 2 4 1 2 0 1 0 2 0 3 1
70 Reena 32 29 87 0.85 100 60 0 3.21 12.2 74 172 91 43 2.11 173 2 0 4 3 0 2 0 1 0 2 0 1 2
71 Fathima 26 35 101 1.2 130 90 0 2.78 14.9 93 194 70 58.6 1.2 194 2 1 3 4 1 1 1 0 0 2 0 3 1
72 Logeshwari 27 29 74 0.81 140 80 0 2.41 8.74 81 200 76 45.2 1.68 200 2 0 3 3 0 2 1 1 0 2 0 2 2
73 Bindu 23 24 70 0.76 130 70 0 4.01 1.62 75 140 78 43 1.81 140 2 0 2 2 0 2 1 1 0 2 0 2 2
74 Umamaheswari 21 31 89 0.82 120 80 0 3.167 10.4 92 159 138 40.7 3.45 159 2 1 2 4 0 2 0 1 0 1 0 2 2
75 Aruna 22 34 74 0.76 130 80 0 2.21 8.72 80 180 132 65 2.03 180 2 0 2 4 0 2 1 0 0 2 0 1 2
76 Prema 23 24.2 89 0.9 110 80 0 3.34 12.6 82 140 72 43 1.67 140 2 1 2 3 1 2 0 1 0 2 0 3 1
77 Thangam 20 23.9 87 0.88 110 70 0 2.101 7 75 157 118 57.6 2.07 157 2 0 1 2 1 2 0 0 0 2 0 1 2
78 Diya 23 29 84 0.8 130 80 0 2.041 9.4 92 160 109 32.5 3.3 160 2 0 2 3 0 2 1 1 0 1 0 2 2
79 Jenitha 22 22.6 73 0.85 110 80 0 1.76 2.36 80 190 135 54.3 2.5 190 2 0 2 2 0 2 0 0 0 2 0 0 2
80 Leelavathy 26 30 81 0.8 110 60 0 2.804 8.72 80 121 70 54.3 1.29 121 2 0 3 3 0 2 0 0 0 2 0 0 2
81 Indra 23 30.6 75 0.75 130 80 0 4.11 6.101 79 190 90 43.7 2.09 190 2 0 2 4 0 2 1 1 0 2 0 2 2
82 Geetha 22 23.2 86 0.84 140 90 0 2.04 8.443 75 159 132 38.1 3.42 159 2 0 2 2 0 1 1 1 0 1 0 2 2
83 Komala 21 24 75 0.88 116 80 0 4.169 7 83 180 72 65 1.107 180 2 0 2 2 1 2 0 0 0 2 0 1 2
84 Vidya 25 24 74 0.81 116 76 0 2.54 5.601 85 168 107 43 7 168 2 0 2 2 0 2 0 1 0 1 0 1 2
85 Lalithapriya 28 29 94 0.9 150 90 0 4.07 5.06 86 159 90 36.4 2.6 159 2 1 3 3 1 1 1 1 0 2 0 4 1
86 Sandhiya 20 24.2 80 0.8 140 80 0 0.06 6.71 88 194 61 38 1.605 194 2 0 1 3 0 2 1 1 0 2 0 2 2
87 Thamilselvi 21 26 82 0.82 110 70 0 1.002 4.02 78 103 90 36.4 2.6 103 2 0 2 3 0 2 0 1 0 2 0 1 2
88 Vinatha 25 30 79 0.75 120 80 0 2.016 4.06 74 172 61 38 1.6 172 2 0 2 3 0 2 0 1 0 2 0 1 2
89 Vishalakshi 28 22 79 0.78 110 70 0 2.74 7.73 92 186 136 51 1.31 186 2 0 3 2 0 2 0 0 0 2 0 0 2
90 Banumathy 20 23 79 0.77 120 70 0 2.61 9.06 89 164 107 43 2.42 164 2 0 1 2 0 2 0 1 0 2 0 1 2
91 vijaya 21 24 84 0.82 110 70 0 1.67 4.07 75 104 119 39.6 2.9
92 Edema 28 21 73 0.79 130 80 0 2.78 8.72 88 161 76 45.2 1.68
93 Latha 31 23.5 74 0.81 136 86 0 4.01 7.08 92 191 132 64 2.06
94 Yuvarani 20 22 80 0.88 140 84 0 1.021 8.7 64 172 66 48.3 1.53
95 Kamachi 32 23 73 0.74 110 76 0 3.016 1.212 80 167 61 38 1.6
96 Kanchana 27 22 88 0.91 120 70 0 3.6 0.24 69 191 169 32.5 3.3
97 Janakilakshmi 29 30 82 0.82 124 82 0 1.87 6.87 78 143 115 35.2 3.2
98 haritha 22 24 77 0.85 116 80 0 2.16 9.2 84 160 109 32 3.3
99 jeevatha 26 20 80 0.8 128 74 0 1.213 7.36 96 166 132 65 2.03
100 Deepa 25 19 84 0.9 100 84 0 4.1 8.17 88 206 72 43 1.67
